Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106767 · ClinicalTrials.gov registry record · Phase 1
The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02106767 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 16 participants.
The verdict
NCT02106767, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The effect of transporter inhibition by rifampin on the pharmacokinetics of rosuvastatin will be studied in clinical trial in White and Asian healthy volunteers.
Interventions
- DRUG Rosuvastatin
- DRUG Rosuvastatin plus rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106767
The ClinicalTrials.gov registry entry for NCT02106767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT02106767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106767 about?
NCT02106767 is a clinical study titled "The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin". The effect of transporter inhibition by rifampin on the pharmacokinetics of rosuvastatin will be studied in clinical trial in White and Asian healthy volunteers.
What is the current status of trial NCT02106767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-11. Estimated completion is 2016-08-07.
What interventions are being tested in trial NCT02106767?
The interventions under investigation include: Rosuvastatin (DRUG), Rosuvastatin plus rifampin (DRUG).
Who is sponsoring clinical trial NCT02106767?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.